Inherited metabolic disorders
Early-juvenile metachromatic leukodystrophy
Early-juvenile metachromatic leukodystrophy is a childhood form of an inherited disorder in which sulfatides accumulate and damage myelin. Movement, learning and other neurologic functions can deteriorate.
Other names and abbreviations
EJ-MLD · early-juvenile MLD · ARSA deficiency · metachromatic leukodystrophy · MLD · Early-juvenile arylsulfatase A deficiency · Early-onset juvenile metachromatic leukodystrophy
Where transplant fits
Autologous gene therapy is approved for defined presymptomatic and early-symptomatic early-juvenile MLD populations in the US and some other regions. It uses the patient’s own cells. Donor transplantation may be considered in selected early disease, with outcomes closely linked to stage.
Treatment depends on the exact diagnosis, disease stage, prior treatment and the person’s health. These categories are not estimates of donor demand.
Treatment at a glance
- Who it affects
- An early-childhood presentation within the wider MLD spectrum; clinical stage is as important as the age-based subtype label.
- Other treatment options
- Gene-therapy eligibility depends on the exact disease subtype and retained function. Symptom-directed, rehabilitation and nutritional care remain important.
- Cells used for transplantation
- The patient’s own gene-modified stem cells for eligible gene therapy; suitable donor stem cells only when allogeneic transplantation is selected.
Why the details matter
Advanced neurologic impairment is not covered by the early-disease treatment claims. Neither an approved product nor a donor match guarantees reversal of existing damage.
Questions to bring to your care team
What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?
Sources and further reading
- Arylsulfatase A Deficiency
GeneReviews, University of Washington / NCBI Bookshelf · Accessed 2026-09-05 - LENMELDY: indication and current prescribing information
FDA · Accessed 2026-09-05 - Inborn Errors of Metabolism and Osteopetrosis
EBMT Handbook · 2024-04-11
Understanding can become action.
Some patients need a blood stem cell donor. Others receive different treatment. Wherever your interest began, you can help JBF reach more people who may be able to donate.
Explore the official registry serving where you live. It explains who can join, how registration works and what donation involves.
Find your official registryIf joining is not right for you, a gift to the Jada Bascom Foundation supports education, outreach and referrals to official registries.
Donate to JBFKeep learning
Why matching is hard: an interactive leukemia story
More in inherited metabolic disorders. Sharing a group does not mean sharing a treatment plan.
